Clinical trial · Observational
Longitudinal Pancreatic Cancer Study
A Prospective Longitudinal Study of CA 19-9 as an Aid in Monitoring Disease in Patients With Pancreatic Cancer
NCT02250638CI-TRIAL-00053314completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To obtain sufficient specimens and correlating clinical data from a well-controlled prospective clinical trial collecting longitudinal specimens from subjects diagnosed with any stage of pancreatic cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CA 19-9 Assay | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- A Prospective Longitudinal Study of CA 19-9 as an Aid in Monitoring Disease in Patients with Pancreatic Cancer
- timeFrame
- 3 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Males and females, age≥ 18 years * Histologic/pathologic confirmation of exocrine pancreatic cancer * Any stage of disease: Newly diagnosed, stable, disease progression * Any treatment time point: Treatment naïve, currently receiving or completed therapy for pancreatic cancer including active monitoring. * Individuals with a history of malignant disease other than pancreatic cancer that was resected greater than 5 years ago and are currently in remission are eligible. * Life expectancy greater than 6 months * Able to understand and willing to provide informed consent Exclusion Criteria: * Males and females, age \<18 years * No histologic/pathologic confirmation of exocrine pancreatic cancer * Life expectancy less than 6 months * Any concurrent malignancy other than basal or squamous cell skin cancers or in-situ cervical cancer. * Unable to provide informed consent
References
Publications (0)
Data not yet available
No reference posted for this study.